used in therapeutic procedures targeted to a specific tumor or to part of the tumor
with a high concentration of biomarkers. These sophisticated procedures are tai-
lored to the individual patient’s illness and thoroughly represent personalized
diagnostics and therapy.
References
Abdel Razek AA, Kandeel AY, Soliman N, El-shenshawy HM, Kamel Y, Nada N, Denewar A
(2007) Role of diffusion-weighted echo-planar MR imaging in differentiation of residual or
recurrent head and neck tumors and posttreatment changes. AJNR Am J Neuroradiol 28
(6):1146–1152. doi:10.3174/ajnr.A0491
Atreya R, Neumann H, Neufert C, Waldner MJ, Billmeier U, Zopf Y, Willma M, App C,
Munster T, Kessler H, Maas S, Gebhardt B, Heimke-Brinck R, Reuter E, Dorje F, Rau TT,
Uter W, Wang TD, Kiesslich R, Vieth M, Hannappel E, Neurath MF (2014) In vivo imaging
using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn’s
disease. Nat Med 20(3):313–318. doi:10.1038/nm.3462
Basu S (2010) Personalized versus evidence-based medicine with PET-based imaging. Nat Rev
Clin Oncol 7(11):665–668. doi:10.1038/nrclinonc.2010.121
Bessho F (1996a) Effects of mass screening on age-specific incidence of neuroblastoma. Int J
Cancer 67(4):520–522. doi:10.1002/(SICI)1097-0215(19960807)67:4<520::AID-IJC10>3.0.
CO;2-B
Bessho F (1996b) Where should neuroblastoma mass screening go? Lancet 348(9043):1672.
doi:10.1016/S0140-6736(05)65814-X
Bombardieri E (2006) The added value of metabolic imaging with FDG-PET in oesophageal
cancer: prognostic role and prediction of response to treatment. Eur J Nucl Med Mol Imaging
33(7):753–758. doi:10.1007/s00259-006-0147-x
Brodbelt A (2011) Clinical applications of imaging biomarkers. Part 2. The neurosurgeon’s
perspective. Br J Radiol 84(Spec No 2):S205–208. doi:10.1259/bjr/19282704
Buckler AJ, Mozley PD, Schwartz L, Petrick N, McNitt-Gray M, Fenimore C, O’Donnell K,
Hayes W, Kim HJ, Clarke L, Sullivan D (2010) Volumetric CT in lung cancer: an example for
the qualification of imaging as a biomarker. Acad Radiol 17(1):107–115. doi:10.1016/j.acra.
2009.06.019
Burgel U, Amunts K, Hoemke L, Mohlberg H, Gilsbach JM, Zilles K (2006) White matter fiber
tracts of the human brain: three-dimensional mapping at microscopic resolution, topography
and intersubject variability. Neuroimage 29(4):1092–1105. doi:10.1016/j.neuroimage.2005.
08.040
Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol
7(7):505–516. doi:10.1038/nrm1962
Crommelin DJ, Storm G, Luijten P (2011)‘Personalised medicine’through‘personalised medi-
cines’: time to integrate advanced, non-invasive imaging approaches and smart drug delivery
systems. Int J Pharm 415(1-2):5–8. doi:10.1016/j.ijpharm.2011.02.010
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S,
Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J
(2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version
1.1). Eur J Cancer 45(2):228–247. doi:10.1016/j.ejca.2008.10.026
European Society of Radiology (2011) Medical imaging in personalised medicine: a white paper
of the research committee of the European Society of Radiology (ESR). Insights Imaging 2
(6):621–630. doi:10.1007/s13244-011-0125-0
Evans WE, Johnson JA (2001) Pharmacogenomics: the inherited basis for interindividual differ-
ences in drug response. Annu Rev Genomics Hum Genet 2:9–39. doi:10.1146/annurev.genom.
2.1.9
228 D. Miletic ́et al.